NurExone Biologic Inc. (NRX) — research page
CA · ca-cm-kg/TSXV/NRX · as of 2026-11-06
Identity and listing
The issuer is NurExone Biologic Inc., listed on the TSXV under ticker NRX. Its ISIN is CA67059R1091 and its LEI is 25490047UWNZ2P8ESB77. Its security type is Corporate, its sector is Life Sciences, and its jurisdiction is Ontario, Canada. Its segment is not on the record. Its listing status is listed, not halted.
| field | value | source · read date |
|---|---|---|
| name | NurExone Biologic Inc. | source · 2026-11-06 |
| exchange | TSXV | source · 2026-11-06 |
| ticker | NRX | source · 2026-11-06 |
| ISIN | CA67059R1091 | source · 2026-11-06 |
| LEI | 25490047UWNZ2P8ESB77 | source · 2026-11-06 |
| security type | Corporate | source · 2026-11-06 |
| segment | not on the record | |
| sector | Life Sciences | source · 2026-11-06 |
| jurisdiction | Ontario, Canada | source · 2026-11-06 |
| status | listed, not halted | source · 2026-11-08 |
The disclosure read
The record holds 9 filings in the twelve months to 2026-11-06, on 9 filing days. Of these, 3 are exchange bulletins and 6 are newswire releases. The median gap between filing days is 10.5 days. The latest filing is dated 2026-10-30 and is a newswire release, 7 days before the record date. The exchange median is 19 days cadence, 9 filings and 17.0 days latency across 1427 TSXV issuers. The sector median is 17.5 days cadence, 7.0 filings and 14 days latency across 200 Life Sciences issuers.
| filings | median gap between filing days | days from latest filing to as-of | |
|---|---|---|---|
| this issuer | 9 | 10.5 | 7 |
| exchange median: TSXV (1427 issuers) | 9 | 19 | 17 |
| sector median: Life Sciences (200 issuers) | 7 | 17.5 | 14 |
| date | type | category | filing |
|---|---|---|---|
| 2026-10-30 | newswire_release | NurExone Demonstrates Consistent Anti-Inflammatory Activity | |
| 2026-10-22 | newswire_release | NurExone Demonstrates Scalable Exosome Production, | |
| 2026-10-09 | newswire_release | NurExone Advances Optic Nerve Injury Program Toward | |
| 2026-09-18 | newswire_release | NurExone Expands U.S. Engagement Across Four Major Boston | |
| 2026-09-16 | newswire_release | NurExone Announces Voting Results of Annual General and |
window 2025-11-06 to 2026-11-06 · the node's disclosure lines, as get_filings serves them
Auditor
The auditor is not on the record, as none was found. Its location is not on the record. The record holds no auditor changes.
Events and halts
The record holds no listing, delisting, name change, domicile change or segment move events. The issuer is listed, not halted.
Orderability
Under rule version acm-68000/ca/kyp-know-your-product-ni-31-103/r1, as of 2026-11-04, the outcome is determinable for both client categories. Paragraph (o) of the definition and paragraph (q) of the definition each carry signal ACM-200.
| client category | outcome |
|---|---|
| Paragraph (o) of the definition | ACM-200 |
| Paragraph (q) of the definition | ACM-200 |
rule acm-68000/ca/kyp-know-your-product-ni-31-103/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability
Coverage
The issuer's investor-relations page names 7 research houses: Zacks Small Cap Research, Poschevale Securities, Tormont Group LLC, Fundamental Research Corp., Litchfield Hills Research LLC, Morningstar and WTR.
| research house | analyst | source · read date |
|---|---|---|
| Zacks Small Cap Research | issuer page · 2026-11-12 | |
| Poschevale Securities | issuer page · 2026-11-12 | |
| Tormont Group LLC | issuer page · 2026-11-12 | |
| Fundamental Research Corp. | issuer page · 2026-11-12 | |
| Litchfield Hills Research LLC | issuer page · 2026-11-12 | |
| Morningstar | issuer page · 2026-11-12 | |
| WTR | Robert Sassoon | issuer page · 2026-11-12 |
Open research
The record holds 5 openly published research notes. Water Tower Research LLC published on 2026-05-21 and 2026-04-21. Zacks Small-Cap Research published on 2025-07-09. Poschevale Securities published on 2025-03-01 and 2024-07-01.
| date | publisher | note | kind |
|---|---|---|---|
| 2026-05-21 | Water Tower Research LLC | NRX: Initiating Coverage; A Novel Exosome Platform at the Frontier of CNS Regeneration | issuer-sponsored |
| 2026-04-21 | Water Tower Research LLC | NRX: From Preclinical Promise to Clinical Execution - De-Risking the Exosome Opportunity in CNS | issuer-sponsored |
| 2025-07-09 | Zacks Small-Cap Research | NRXBF: Test Results Show Spinal Injury Recovery | issuer-sponsored |
| 2025-03-01 | Poschevale Securities | NurExone Biologic Inc. research report | issuer-sponsored |
| 2024-07-01 | Poschevale Securities | ExoPTEN | issuer-sponsored |
Licensed
Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.
| licensor | entitlement | title | date | source |
|---|---|---|---|---|
| none loaded |
As-of depth
The market's vintage is not sealed. The record holds no sealed issuer years, and the market has no earliest sealed date. The live record began on 2026-09-10. The store holds sealed years 2021 through 2026 for this issuer, but these are not served as of a date, and the as-of answer is not_sealed.
Sources
14 source pages are named on this page; every value above carries its own source page and read date in the numbers.
- 10.1
- https://www.tsx.com/json/company-directory/search/tsxv/^* (identity.exchange)
- 10.2
- https://www.marketscreener.com/quote/stock/NUREXONE-BIOLOGIC-INC-139971056/finances (identity.isin)
- 10.3
- https://api.gleif.org/api/v1/lei-records/25490047UWNZ2P8ESB77 (identity.jurisdiction)
- 10.4
- https://www.tsx.com/en/resource/571 (identity.sector)
- 10.5
- https://mcp.ca-cm-kg.ai/events/TSXV/NRX (the disclosure lines)
- 10.6
- https://iiroc.mediaroom.com/index.php?s=2429&l=100 (the halt flag)
- 10.7
- https://mcp.ca-cm-kg.ai/book/aio.json (the orderability chapter)
- 10.8
- https://nurexone.com/investors/ (coverage)
- 10.9
- https://nurexone.com/wp-content/uploads/2026/05/NRX-Initiating-Coverage_-A-Novel-Exosome-Platform-at-the-Frontier-of-CNS-Regeneration-May-21-2026.pdf (open research)
- 10.10
- https://nurexone.com/wp-content/uploads/2026/04/MS_NRX-From-Preclinical-Promise-to-Clinical-Execution-De-Risking-the-Exosome-Opportunity-in-CNS-April-21-2026.pdf (open research)
- 10.11
- https://nurexone.com/wp-content/uploads/2025/07/Zacks_SCR_Research_07092025_NRXBF_Sorensen.pdf (open research)
- 10.12
- https://nurexone.com/wp-content/uploads/2025/04/Nurexone_Biologic_Inc_Poschevale_Report_March_2025_1743438611.pdf (open research)
- 10.13
- https://nurexone.com/wp-content/uploads/2024/08/Analyst-Report-on-NurExone.pdf (open research)
- 10.14
- https://mcp.ca-cm-kg.ai/record/TSXV/NRX (the record)
Read it by agent
The same page, signed and receipted: get_research at https://mcp.getresearch.ai/mcp with {"isin":"CA67059R1091"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:1e7079675e903e06.